Literature DB >> 18215333

Enhancement of atomoxetine serum levels by co-administration of paroxetine.

Michael Paulzen, Hans-Willi Clement, Gerhard Gründer.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18215333     DOI: 10.1017/S1461145707008115

Source DB:  PubMed          Journal:  Int J Neuropsychopharmacol        ISSN: 1461-1457            Impact factor:   5.176


× No keyword cloud information.
  4 in total

Review 1.  Clinical Pharmacogenetics Implementation Consortium Guideline for Cytochrome P450 (CYP)2D6 Genotype and Atomoxetine Therapy.

Authors:  Jacob T Brown; Jeffrey R Bishop; Katrin Sangkuhl; Erika L Nurmi; Daniel J Mueller; Jean C Dinh; Andrea Gaedigk; Teri E Klein; Kelly E Caudle; James T McCracken; Jose de Leon; J Steven Leeder
Journal:  Clin Pharmacol Ther       Date:  2019-04-13       Impact factor: 6.875

2.  Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II.

Authors:  Shu-Feng Zhou
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

3.  Relationship between atomoxetine plasma concentration, treatment response and tolerability in attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder.

Authors:  Philip Hazell; Katja Becker; Eija A Nikkanen; Paula T Trzepacz; Yoko Tanaka; Linda Tabas; Deborah N D'Souza; Jennifer Witcher; Amanda Long; George Ponsler; Ralf W Dittmann
Journal:  Atten Defic Hyperact Disord       Date:  2009-09-23

4.  Therapeutic drug monitoring of atomoxetine in children and adolescents with attention-deficit/ hyperactivity disorder: a naturalistic study.

Authors:  Katrin Ruppert; Christoph Geffert; Hans-Willi Clement; Christian Bachmann; Michael Haberhausen; Eberhard Schulz; Christian Fleischhaker; Monica Biscaldi-Schäfer
Journal:  J Neural Transm (Vienna)       Date:  2022-04-07       Impact factor: 3.850

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.